Literature DB >> 29024890

A systematic review of economic evaluation in pancreatic ductal adenocarcinoma.

Claire Gérard1, Philippe Fagnoni2, Angélique Vienot3, Christophe Borg4, Samuel Limat1, Franck Daval5, François Calais5, Julie Vardanega6, Marine Jary4, Virginie Nerich7.   

Abstract

OBJECTIVES: The economic evaluation (EE) of healthcare interventions has become a necessity. However, high quality needs to be ensured in order to achieve validated results and help making informed decisions. Thus, the objective of the present study was to systematically identify and review published pancreatic ductal adenocarcinoma-related EEs and to assess their quality.
METHODS: Systematic literature research was conducted in PubMed and Cochrane to identify published EEs between 2000 and 2015. The quality of each selected EE was assessed by two independent reviewers, using the Drummond's checklist.
RESULTS: Our systematic review was based on 32 EEs and showed a wide variety of methodological approaches, including different perspectives, time horizon, and cost effectiveness analyses. Nearly two-thirds of EEs are full EEs (n = 21), and about one-third of EEs had a Drummond score ≥7, synonymous with 'high quality'. Close to 50% of full EEs had a Drummond score ≥7, whereas all of partial EEs had a Drummond score <7 (n = 11).
CONCLUSIONS: Over the past 15 years, a lot of interest has been evinced over the EE of pancreatic ductal adenocarcinoma (PDAC) and its direct impact on therapeutic advances in PDAC. To provide a framework for health care decision-making, to facilitate transferability and to lend credibility to health EEs, their quality must be improved. For the last 4 years, a tendency towards a quality improvement of these studies has been observed, probably coupled with a context of rational decision-making in health care, a better and wider spread of recommendations and thus, medical practitioners' full endorsement.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cost-effectiveness analysis; Cost-utility analysis; Economic evaluation; Pancreatic ductal adenocarcinoma; Quality-adjusted life years

Mesh:

Year:  2017        PMID: 29024890     DOI: 10.1016/j.ejca.2017.08.035

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

Review 1.  Research on the Economics of Cancer-Related Health Care: An Overview of the Review Literature.

Authors:  Amy J Davidoff; Kaitlin Akif; Michael T Halpern
Journal:  J Natl Cancer Inst Monogr       Date:  2022-07-05

2.  Utility values and its time to deterioration in breast cancer patients after diagnosis and during treatments.

Authors:  Rana El Haidari; Amelie Anota; Tienhan S Dabakuyo-Yonli; Francis Guillemin; Thierry Conroy; Michel Velten; Damien Jolly; Sylvain Causeret; Jean Cuisenier; Olivier Graesslin; Linda Abou Abbas; Virginie Nerich
Journal:  Qual Life Res       Date:  2022-05-19       Impact factor: 3.440

3.  Cost-effectiveness of adding atezolizumab to first-line chemotherapy in patients with advanced triple-negative breast cancer.

Authors:  Bin Wu; Fei Ma
Journal:  Ther Adv Med Oncol       Date:  2020-05-05       Impact factor: 8.168

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.